Mast Therapeutics Inc (NYSEMKT:MSTX) and Savara announced that, pending completion of their proposed merger, the combined company’s common stock has been approved for …
Mast Therapeutics Inc (NYSEMKT:MSTX) reported financial results for the fourth quarter and year ended December 31, 2016. “We are pleased with the progress …
Mast Therapeutics Inc (NYSEMKT:MSTX) and Savara, a privately held pharmaceutical firm aimed at treating rare respiratory diseases captivated the attention of investors in …
Mast Therapeutics Inc (NYSEMKT:MSTX) and privately held pharmaceutical firm Savara Inc. have announced the intent to merge to advance a novel pipeline of …
Mast Therapeutics Inc (NYSEMKT:MSTX) reported that the first patient has been enrolled in an investigator-sponsored Phase 2 study of the Company’s lead product …
By Brett Eversole U.S.
Mast Therapeutics Inc (NYSEMKT:MSTX) reported financial results for the quarter ended September 30, 2016. “We are rapidly advancing the clinical development of AIR001 in …
Today, shareholders of Mast Therapeutics Inc (NYSEMKT:MSTX) woke up to a nice 15% pop in the value of their shares, after the drug …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
Mast Therapeutics Inc (NYSEMKT:MSTX) investors cheer the news that the company’s subsidiary, Aires Pharmaceuticals, has entered into a collaborative agreement with Philips Respironics related to …